Targeted multigene panel testing involves the screening of various established hereditary breast and ovarian cancer genes as described above, simultaneously at costs often reported as lower than testing for BRCA1 and BRCA2 alone (17). This evidence concerns the gene BRCA1 and ovarian carcinoma.